Clincosm LogoSign in Get a demo

Retrospective Study of Germ Cell Tumors of the Central Nervous System

Sponsor
Beijing Sanbo Brain Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05836701
Collaborator
(none)
500
Enrollment
1
Location
20
Anticipated Duration (Months)
24.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Retrospectively analyzing the epidemiological and clinical characteristics, treatment, recurrence, prognosis and prognostic factors of the germ-cell tumors of central nervous system in a single center.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Clinical data of patients with germ-cell tumors of central nervous system who were treated in the Department of Neuro-oncology, Sanbo Brain Hospital Capital Medical University between January 2007 and December 2022 were retrospectively collected, and the epidemiological and clinical characteristics, treatment, recurrence, prognosis and prognostic factors of the disease were analyzed.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Single-center Retrospective Study of Germ Cell Tumors of the Central Nervous System
    Anticipated Study Start Date :
    May 1, 2023
    Anticipated Primary Completion Date :
    Dec 31, 2023
    Anticipated Study Completion Date :
    Dec 31, 2024

    Outcome Measures

    Primary Outcome Measures

    1. epidemiological characteristics [1 year]

    2. treatment regimen [1 year]

    3. relapse pattern [1 year]

    4. prognostic factor [1 year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Clinically or pathologically diagnosed as germ cell tumor of the central nervous system.

    • Have received antitumor therapy.

    • Patients who were clinically diagnosed based on neuroimaging characteristics and response to radiotherapy or chemotherapy were allowed for enrollment.

    Exclusion Criteria:
    • Patients with missing key information such as tumor location, surgical, chemotherapy and radiotherapy data, and post-treatment evaluation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sanbo Brain Hospital Capital Medical University Beijing China

    Sponsors and Collaborators

    • Beijing Sanbo Brain Hospital

    Investigators

    • Principal Investigator: Jun-ping Zhang, Capital Medical University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Junping Zhang, Director of Neuro-Oncology, Beijing Sanbo Brain Hospital
    ClinicalTrials.gov Identifier:
    NCT05836701
    Other Study ID Numbers:
    • CNS-GCT-R
    First Posted:
    May 1, 2023
    Last Update Posted:
    May 6, 2023
    Last Verified:
    May 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Neoplasms, Germ Cell and Embryonal
    Central Nervous System Neoplasms

    Study Results

    No Results Posted as of May 6, 2023